Is PCRAF or ABBV a better dividend investment in 2026?

PCRAF currently yields 7181.33% with a 5% 5-year dividend growth rate. ABBV yields 3.06% with 8.9% growth. The better choice depends on your goal: PCRAF offers higher current income.

What is the dividend yield difference between PCRAF and ABBV?

PCRAF has a forward dividend yield of 7181.33% ($2.00/share annually). ABBV yields 3.06% ($6.65/share annually). The yield gap is 7178.27 percentage points.

Home › Compare › PCRAF vs ABBV

PCRAF vs ABBV: Dividend Comparison 2026

PCRAF yields 7181.33% · ABBV yields 3.06%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 PCRAF wins by $2129323467795842.25M in total portfolio value

INVESTMENT

TIME HORIZON10 years

PCRAF

● Live price

7181.33%

Share price

$0.03

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$2129323467795842.25M

Annual income

$2,072,550,944,745,044,800,000.00

Full PCRAF calculator →

ABBV

AbbVie Inc.

● Live price

3.06%

Share price

$217.44

Annual div

$6.65

5Y div CAGR

40.6%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$102.3K

Annual income

$24,771.77

Full ABBV calculator →

Portfolio growth — PCRAF vs ABBV

📍 PCRAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	PCRAF	ABBV
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, PCRAF + ABBV cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

PCRAF pays

ABBV pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PCRAF

Annual income on $10K today (after 15% tax)

$610,412.93/yr

After 10yr DRIP, annual income (after tax)

$1,761,668,303,033,288,000,000.00/yr

ABBV

Annual income on $10K today (after 15% tax)

$259.96/yr

After 10yr DRIP, annual income (after tax)

$21,056.00/yr

At 15% tax rate, PCRAF beats the other by $1,761,668,303,033,288,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PCRAF + ABBV for your $10,000?

PCRAF: 50%ABBV: 50%

100% ABBV50/50100% PCRAF

Portfolio after 10yr

$1064661733897921.13M

Annual income

$1,036,275,472,372,522,400,000.00/yr

Blended yield

97.33%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

PCRAF

No analyst data

Altman Z

-16.9

Piotroski

0/9

ABBV

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$256.15

+17.8% upside vs current

Range: $223.00 — $299.00

Altman Z

2.0

Piotroski

8/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PCRAF buys

ABBV buys

No recent congressional trades found for PCRAF or ABBV in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricPCRAFABBV

Forward yield	7181.33% ✓	3.06%
Annual dividend / share	$2.00	$6.65 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	40.6% ✓
Portfolio after 10y	$2129323467795842.25M ✓	$102.3K
Annual income after 10y	$2,072,550,944,745,044,800,000.00 ✓	$24,771.77
Total dividends collected	$2125520801706147.50M ✓	$61.0K
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: PCRAF vs ABBV ($10,000, DRIP)

Year	PCRAF Portfolio	PCRAF Income/yr	ABBV Portfolio	ABBV Income/yr	Gap
1← crossover	$728,833	$718,132.85	$11,550	$430.00	+$717.3K → PCRAF
2	$49,695,629	$48,915,777.42	$13,472	$627.96	+$49.68M → PCRAF
3	$3,170,308,012	$3,117,133,689.10	$15,906	$926.08	+$3170.29M → PCRAF
4	$189,238,958,407	$185,846,728,834.15	$19,071	$1,382.55	+$189238.94M → PCRAF
5	$10,570,133,462,966	$10,367,647,777,471.07	$23,302	$2,095.81	+$10570133.44M → PCRAF
6	$552,520,748,327,293	$541,210,705,521,919.44	$29,150	$3,237.93	+$552520748.30M → PCRAF
7	$27,030,543,997,490,970	$26,439,346,796,780,764.00	$37,536	$5,121.41	+$27030543997.45M → PCRAF
8	$1,237,774,696,255,956,700	$1,208,852,014,178,641,400.00	$50,079	$8,338.38	+$1237774696255.91M → PCRAF
9	$53,058,432,757,754,490,000	$51,734,013,832,760,615,000.00	$69,753	$14,065.80	+$53058432757754.41M → PCRAF
10	$2,129,323,467,795,842,200,000	$2,072,550,944,745,044,800,000.00	$102,337	$24,771.77	+$2129323467795842.25M → PCRAF

PCRAF vs ABBV: Complete Analysis 2026

PCRAF — Stock

Pucara Gold Ltd. engages in the acquisition, exploration, and evaluation of mineral properties in Peru. The company explores for gold, copper, zinc, lead, and silver deposits. Its project portfolio includes the Lourdes, Pacaska, Capricho, Guadalupe, Keyla, Paco Orco, Pucapaca, and Santo Tomas Projects located in Peru. Pucara Gold Ltd. is based in Vancouver, Canada.

Full PCRAF Calculator →

ABBV — Healthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →

📬

Get this PCRAF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PCRAF vs SCHD PCRAF vs JEPI PCRAF vs O PCRAF vs KO PCRAF vs MAIN PCRAF vs JNJ PCRAF vs MRK PCRAF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.